Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
| PRME Etf | USD 3.27 0.08 2.39% |
About 61% of Prime Medicine,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Prime Medicine, Common suggests that many traders are alarmed. The current market sentiment, together with Prime Medicine,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Prime Medicine, Common etf news signals to limit their universe of possible portfolio assets.
Prime Medicine, etf news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Prime daily returns and investor perception about the current price of Prime Medicine, Common as well as its diversification or hedging effects on your existing portfolios.
Prime |
Collaboration Combines Prime Medicines Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibbs Broad Expertise in Development and Commercialization of Novel Cell Therapies Prime Medicine to Receive 110 Million Upfront, with Potential for More Than 3.5 Billion in Milestones, Including 1.4 Billion in Development Milestones and More Than 2.1 Billion in Commercialization Milestones CAMBRIDGE, Mass., Sept. 30, 2024 -- Prime Medicine, Inc. today an
Read at finance.yahoo.com
 |
Prime Medicine, Fundamental Analysis
We analyze Prime Medicine,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Prime Medicine, is currently under evaluation in shares outstanding as compared to similar ETFs. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Prime Medicine, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prime Medicine, etf to make a market-neutral strategy. Peer analysis of Prime Medicine, could also be used in its relative valuation, which is a method of valuing Prime Medicine, by comparing valuation metrics with similar companies.
Peers
Prime Medicine, Related Equities
| CRBU | Caribou Biosciences | 9.30 | ||||
| EDIT | Editas Medicine | 6.72 | ||||
| NTLA | Intellia Therapeutics | 5.52 | ||||
| BEAM | Beam Therapeutics | 3.86 | ||||
| CRSP | Crispr Therapeutics | 3.44 | ||||
| RLAY | Relay Therapeutics | 3.39 | ||||
| VERV | Verve Therapeutics | 2.72 | ||||
| SANA | Sana Biotechnology | 2.34 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| DNA | Ginkgo Bioworks | 0.95 | ||||
| RPRX | Royalty Pharma | 0.35 | ||||
| IPSC | Century Therapeutics | 5.41 | ||||
| OCEA | Ocean Biomedical | 5.48 |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.